Thomas Malley

CIK: 0001403322

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (15.8%)

Position reduction

Option Exercises (M)10 (52.6%)

Derivative conversions

Awards (A)6 (31.6%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

KURA

Kura Oncology, Inc.

Director

KNSA

Kiniksa Pharmaceuticals International, plc

Director

Discretionary Trading P&L

Holdings

Transaction History (19 total)

KURA
Kura Oncology, Inc.
Jun 4, 2026
Award(A)
Option to purchase common stock
Direct
35K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
May 29, 2026
Exercise(M)
Direct
2.8K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
May 29, 2026
Award(A)
Share Option
Direct
12.2K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
May 29, 2026
Award(A)
Restricted Share Units
Direct
2K shares-
KURA
Kura Oncology, Inc.
Mar 18, 2026
Exercise(M)
Direct
10K shares at avg. $3.12$31K
KNSA
Kiniksa Pharmaceuticals International, plc
Aug 14, 2025
Sale(S)
Direct
78.2K shares at avg. $33.09$2.6M
KNSA
Kiniksa Pharmaceuticals International, plc
Aug 14, 2025
Exercise(M)
Direct
18.8K shares at avg. $15.47$290K
KNSA
Kiniksa Pharmaceuticals International, plc
Aug 14, 2025
Exercise(M)
Direct
33.2K shares at avg. $14.33$476K
KNSA
Kiniksa Pharmaceuticals International, plc
Aug 14, 2025
Exercise(M)
Direct
26.2K shares at avg. $15.19$399K
KNSA
Kiniksa Pharmaceuticals International, plc
Aug 13, 2025
Exercise(M)
Direct
20.1K shares at avg. $10.36$209K
KNSA
Kiniksa Pharmaceuticals International, plc
Aug 13, 2025
Exercise(M)
Direct
30K shares at avg. $9.88$296K
KNSA
Kiniksa Pharmaceuticals International, plc
Aug 13, 2025
Sale(S)
Direct
50.1K shares at avg. $33.32$1.7M
KNSA
Kiniksa Pharmaceuticals International, plc
Aug 12, 2025
Exercise(M)
Direct
22K shares at avg. $1.86$41K
KNSA
Kiniksa Pharmaceuticals International, plc
Aug 12, 2025
Sale(S)
Direct
49.4K shares at avg. $32.40$1.6M
KNSA
Kiniksa Pharmaceuticals International, plc
Aug 12, 2025
Exercise(M)
Direct
27.4K shares at avg. $3.80$104K
KURA
Kura Oncology, Inc.
Jun 5, 2025
Award(A)
Option to purchase common stock
Direct
28.5K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Jun 5, 2025
Exercise(M)
Direct
3.2K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Jun 3, 2025
Award(A)
Restricted Share Units
Direct
2.8K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Jun 3, 2025
Award(A)
Share Option
Direct
16.8K shares-

		Type	Shares	Price		Ownership
Jun 4, 2026	KURA Kura Oncology, Inc.	Award(A) Option to purchase common stock	35,000	-	-	Direct
May 29, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	2,799	-	$0	Direct
May 29, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Share Option	12,158	-	-	Direct
May 29, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Restricted Share Units	2,026	-	-	Direct
Mar 18, 2026	KURA Kura Oncology, Inc.	Exercise(M)	10,000	$3.12	$31,200	Direct
Aug 14, 2025	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	78,233	$33.09	$2,588,730	Direct
Aug 14, 2025	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	18,760	$15.47	$290,217	Direct
Aug 14, 2025	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	33,237	$14.33	$476,286	Direct
Aug 14, 2025	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	26,236	$15.19	$398,525	Direct
Aug 13, 2025	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	20,129	$10.36	$208,536	Direct
Aug 13, 2025	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	30,000	$9.88	$296,400	Direct
Aug 13, 2025	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	50,129	$33.32	$1,670,298	Direct
Aug 12, 2025	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	21,959	$1.86	$40,844	Direct
Aug 12, 2025	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	49,407	$32.40	$1,600,787	Direct
Aug 12, 2025	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	27,448	$3.80	$104,302	Direct
Jun 5, 2025	KURA Kura Oncology, Inc.	Award(A) Option to purchase common stock	28,500	-	-	Direct
Jun 5, 2025	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	3,173	-	-	Direct
Jun 3, 2025	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Restricted Share Units	2,799	-	-	Direct
Jun 3, 2025	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Share Option	16,798	-	-	Direct

1-19 of 19 transactions

About Malley Thomas

Malley Thomas (SEC CIK 0001403322) files insider reports with the SEC as Director of Kura Oncology, Inc. (KURA) and Director of Kiniksa Pharmaceuticals International, plc (KNSA).

Signal8 holds 6 ownership filings by Malley Thomas, all Form 4s, filed between Jun 5, 2025 and Jun 4, 2026. Those filings report 19 transactions, from Jun 3, 2025 to Jun 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Malley Thomas's filings is in LONDON.

Recent filings by Malley Thomas

Jun 4, 2026: Grant or award of KURA derivative securities (Form 4, code A).
May 29, 2026: Option exercise of KNSA shares (Form 4, code M).
May 29, 2026: Grants or awards of KNSA derivative securities (2 lines, Form 4, code A).
Mar 18, 2026: Option exercise of KURA shares (Form 4, code M).
Aug 14, 2025: Open-market sale of KNSA shares (Form 4, code S).

Other insiders filing for Kura Oncology, Inc. (KURA)

Bair Teresa Brophy, Chief Legal Officer
FORD KATHLEEN, Chief Operating Officer
Leoni Mollie, Chief Medical Officer
DOYLE THOMAS JAMES, SVP, Finance & Accounting
Powl Brian T., Chief Commercial Officer
Burrows Francis, Chief Scientific Officer

How to read Form 4 transaction codes